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ABSTRACT
Background: The species of the Bacteroides fragilis group are important components of human microbiota, but as oppor-
tunistic pathogens they can be the causative agents of severe infections.
Methods: The major aims of our investigation were the evaluation of the susceptibility of 400 different Hungarian B. fragilis
group isolates to 10 antibiotics by the agar dilution method, the comparison of our resistance data with previous national
and international antibiotic resistance data and the comparison of present data in regional aspect. The MIC-values on 10
antibiotics of all the strains were determined with the agar dilution method by CLSI. The presence of the cfiA gene in
Division II B. fragilis strains was confirmed by RT-PCR.
Results: We detected a relatively high resistance rate of ampicillin, moxifloxacin, clindamycin and tetracycline, but amoxicil-
lin/clavulanic acid, metronidazole, tigecycline and chloramphenicol showed excellent activity. In this study, we found that
6.75% of the isolates were resistant to cefoxitin and 7% to meropenem, while 8.58% of our B. fragilis strains harboured the
cfiA gene. Most of the meropenem resistant strains were isolated in one of the participating centres. In the case of merope-
nem, cefoxitin, clindamycin and high-level-ampicillin-resistant strains, we found significant regional differences.
Discussion: Most of the results of our study were concordant with previous national and international data, with the excep-
tion of amoxicillin/clavulanic acid, cefoxitin and meropenem.
Conclusions: Our study highlighted the importance of the periodic monitoring of the antimicrobial susceptibility of
Bacteroides species providing important information for the appropriate therapy.
KEYWORDS
Bacteroides species
agar dilution
antibiotic susceptibility test
ARTICLE HISTORY
Received 16 August 2017
Revised 24 November 2017
Accepted 4 December 2017
CONTACT
Edit Urban
urban.edit@med.u-szeged.hu
Department of Clinical Microbiology,
University of Szeged, H-6725 Szeged, Semmelweis
Str. 6., Szeged, Hungary
 2018 Society for Scandinavian Journal of Infectious Diseases
Background
The Bacteroides fragilis group species are very important
members of human microbiota; however, as opportunis-
tic pathogens these clinical isolates can cause severe or
sometimes fatal infections (e.g. skin and soft tissue,
wound, intraabdominal infections, sepsis and abscesses)
[1]. b-lactam/b-lactamase inhibitor combinations, cepha-
mycins, carbapenems, clindamycin, fourth-generation flu-
oroquinolones and 5-nitroimidazoles are used for the
therapy of Bacteroides sp. infections and antibiotic sus-
ceptibility tests are performed for the above-mentioned
drugs in these types of infections [2]. In the last few dec-
ades, the increasing antimicrobial resistance among
Bacteroides isolates is a growing problem worldwide
[2,3]. The routine antimicrobial susceptibility testing of
anaerobic isolates is only recommended by the Clinical
and Laboratory Standards Institute (CLSI), in particular cir-
cumstances [4]: (i) relapse after initially successful therapy,
(ii) failing to response to the empirical therapy, (iii) samples
taken from physiologically sterile body sites, (iv) few avail-
able antibiotic susceptibility data, (v) often resistant isolate
to antianaebic drugs and (vi) required prolonged therapy
[4,5]. Susceptibility testing is recommended in case of epi-
demiological surveillance and highly virulence bacteria
(e.g. Bacteroides, Prevotella, Fusobacterium, Clostridium spp.,
Bilophila wadsworthia and Sutterella wadsworthensis) [4,5].
The antimicrobial susceptibility of Bacteroides isolates
varies among different species and depend on geograph-
ical location [6,7]. For these reasons, the accurate identifica-
tion of isolates, regular performance of antimicrobial
susceptibility surveys and a knowledge of local antimicro-
bial resistance data are essential. A comprehensive anti-
microbial survey among B. fragilis group isolates in
Hungary had not been performed for over 20 years.
Aims and methods
Aims
The objectives of our investigation were as follows: (1)
evaluation of the susceptibility of 400 different
Hungarian B. fragilis group isolates to 10 antibiotics by
the agar dilution method, (2) analysis of any certain dif-
ferences in the resistance rate among the species, (3)
comparison of regional resistance data, (4) comparison
of present and former Hungarian data and (5) the data
of this survey with that of international studies.
Bacterial strains and cultivation
In our study, 400 B. fragilis group isolates, collected
between 2014 and 2016 by four Hungarian clinical
microbiological centres (Centre 1: Semmelweis
University, Budapest, Hungary; Centre 2: SYNLAB Ltd.,
Budapest, Hungary; Centre 3: University of Debrecen,
Debrecen, Hungary; Centre 4: University of Szeged,
Szeged, Hungary) were investigated by our team. The
strains (n¼ 10) obtained from the University of Pecs
were investigated with the isolates from the Centre 1.
The collection criteria were the isolation of 100 clinically
relevant, non-repeating samples by each centres. The
strains were stored in brain heart infusion (BHI) broth
supplemented with 20% glycerol at 80 C. All of the
isolates were cultured on Schaedler agar (bioMerieux,
Marcy l'Etoile, France) for 48 hours, at 37 C in an anaer-
obic chamber (Perkin Elmer, Beaconsfield, UK) under
anaerobic conditions (85% N2, 10% CO2, 5% H2). The
identification at the species level was performed in
Centre 4 with Matrix-Assisted Laser Desorption/
Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF
MS, Bruker Daltonik, Bremen, Germany) using Biotyper
Version 3.0 software. The B. fragilis strains were catego-
rized as Division I (cfiA gene negative strains) and Division
II (positive for the cfiA carbapenemase gene) by MALDI-
TOF MS, as described by Fenyvesi et al. earlier [8].
Agar dilution method
The minimal inhibitory concentration (MIC) values for 10
antibiotics were determined with the agar dilution
method according to the CLSI recommendations [4]. The
tested antibiotics were ampicillin, cefoxitin, tetracycline,
tigecycline, chloramphenicol (Sigma-Aldrich Chemie
GmbH, Schnelldorf, Germany), amoxicillin/clavulanic acid
(GlaxoSmithKline, Brentford, UK), meropenem, moxifloxa-
cin (Fresenius Kabi, Mihla, Germany), clindamycin (Pfizer,
New York, NY) and metronidazole (TEVA, Petach Tikva,
Israel). The tested ranges of the antibiotics were the fol-
lowing: ampicillin (2–256mg/l), amoxicillin/calvulanic
acid (0.064/0.032–16/8mg/l), cefoxitin (0.5–256mg/l),
meropenem (0.064–16mg/l), clindamycin (0.064–256mg/
l), metronidazole (0.064–8mg/l), moxifloxacin
(0.064–32mg/l), tetracycline (0.125–256mg/l), tigecycline
(0.064–32mg/l) and chloramphenicol (0.125–32mg/l). We
used fixed concentration of amoxicillin/clavulanic acid
for stock solution (10/2.5mg/ml). For the interpretation
of the MIC-value, either European Committee on
Antimicrobial Susceptibility Testing (EUCAST) (ampicillin,
amoxicillin/clavulanic acid, meropenem, clindamycin and
metronidazole) or CLSI guidelines (cefoxitin, moxifloxa-
cin, tetracycline and chloramphenicol) were used [4,9].
As the tigecycline breakpoints among Bacteroides species
INFECTIOUS DISEASES 373
Table 1. Antimicrobial activities of 10 antibiotics applied on Bacteroides fragilis group isolates.
MIC (mg/ml) % of isolates
Antimicrobial agents Range MIC50 MIC90 Susceptible Intermediate Resistant
Bacteroides fragilis group (n¼ 400)
Ampicillin 2 to >256 64 >256 0.75 1.25 98.00
Amoxicillin/clavulanic acid 0.064–32 0.5 8 87.00 8.50 4.50
Cefoxitin 0.5–256 8 32 77.00 16.25 6.75
Meropenem 0.064–32 0.5 4 88.75 4.25 7.00
Clindamycin 0.064 to >256 2 >256 63.25 0.00 36.75
Metronidazole 0.064–16 0.5 1 99.75 0.00 0.25
Moxifloxacin 0.064–64 1 8 75.00 6.50 18.50
Tetracycline 0.125–256 16 64 28.75 6.00 65.25
Tigecycline 0.064–64 0.5 4 94.75 3.75 1.50
Chloramphenicol 0.125–16 4 8 99.50 0.50 0.00
B. fragilis (n¼ 233)
Ampicillin 2–512 64 >256 0.00 0.00 100.00
Amoxicillin/clavulanic acid 0.064–32 0.5 4 91.87 6.43 1.70
Cefoxitin 1–256 8 16 90.56 6.00 3.44
Meropenem 0.064–32 0.5 8 84.98 5.15 9.87
Clindamycin 0.064 to >256 1 >256 74.25 0.00 25.75
Metronidazole 0.125–4 0.5 1 100.00 0.00 0.00
Moxifloxacin 0.125–64 0.5 8 76.40 8.15 15.45
Tetracycline 0.125–256 32 64 25.75 3.00 71.25
Tigecycline 0.064–32 0.5 4 94.85 4.30 0.85
Chloramphenicol 0.25–8 4 8 100.00 0.00 0.00
B. thetaiotaomicron (n¼ 79)
Ampicillin 2–512 128 >256 1.27 0.00 98.73
Amoxicillin/clavulanic acid 0.064–32 0.25 8 83.54 13.92 2.53
Cefoxitin 0.5–256 16 32 53.16 37.97 8.87
Meropenem 0.125–32 1 2 92.41 6.33 1.26
Clindamycin 0.064 to >256 8 >256 44.30 0.00 55.70
Metronidazole 0.064–4 0.5 1 100.00 0.00 0.00
Moxifloxacin 0.064–32 1 16 75.96 5.06 18.98
Tetracycline 0.125–256 16 64 40.51 5.06 54.43
Tigecycline 0.064–64 0.5 4 94.94 3.80 1.26
Chloramphenicol 0.125–16 4 8 98.74 1.26 0.00
B. vulgatus (n¼ 26)
Ampicillin 4–512 128 >256 0.00 0.00 100.00
Amoxicillin/clavulanic acid 0.125–16 1 16 69.23 23.08 7.70
Cefoxitin 0.5–128 4 64 80.76 7.69 11.55
Meropenem 0.125–32 1 4 84.62 11.54 3.84
Clindamycin 0.064 to >256 4 >256 50.00 0.00 50.00
Metronidazole 0.125–2 0.5 1 100.00 0.00 0.00
Moxifloxacin 0.25–64 2 32 50.00 0.00 50.00
Tetracycline 0.125–64 16 64 19.24 7.69 73.07
Tigecycline 0.064–8 0.25 2 96.16 3.84 0.00
Chloramphenicol 0.5–8 4 8 100.00 0.00 0.00
B. ovatus (n¼ 24)
Ampicillin 2–512 256 >256 8.33 0.00 91.67
Amoxicillin/clavulanic acid 0.064–32 2 16 79.16 12.50 8.33
Cefoxitin 2–128 32 64 41.67 41.67 16.66
Meropenem 0.125–32 1 16 75.00 8.34 16.66
Clindamycin 0.064 to >256 8 >256 45.83 0.00 54.17
Metronidazole 0.125–8 0.5 2 95.83 0.00 4.17
Moxifloxacin 0.25–32 1 32 79.16 0.00 20.84
Tetracycline 0.125–32 8 32 29.16 20.84 50.00
Tigecycline 0.064–8 0.25 4 95.83 4.16 0.00
Chloramphenicol 2–8 8 8 100.00 0.00 0.00
P. distasonis(n¼ 15)
Ampicillin 8 to >256 >256 >256 0.00 0.00 100.00
Amoxicillin/clavulanic acid 0.125–32 4 16 53.33 20.00 26.67
Cefoxitin 2–128 16 128 60.00 20.00 20.00
Meropenem 0.25–4 0.5 4 86.67 13.33 0.00
Clindamycin 0.5 to >256 4 >256 66.67 0.00 33.33
Metronidazole 0.25–2 0.5 1 100.00 0.00 0.00
Moxifloxacin 0.25–2 0.5 1 100.00 0.00 0.00
Tetracycline 0.25–32 16 32 20.00 20.00 60.00
Tigecycline 0.125–4 0.5 2 100.00 0.00 0.00
Chloramphenicol 4–8 8 8 100.00 0.00 0.00
B. uniformis(n¼ 11)
Ampicillin 32 to >256 128 >256 0.00 0.00 100.00
Amoxicillin/clavulanic acid 0.125–2 0.25 2 100.00 0.00 0.00
Cefoxitin 1–64 8 32 81.80 9.10 9.10
Meropenem 0.25–4 0.5 1 90.90 9.10 0.00
Clindamycin 0.064 to >256 >256< >256 45.45 0.00 54.55
(continued)
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have not yet been established either by EUCAST or CLSI,
the breakpoints published by Nagy et al. were applied
for the interpretation [3]. B. fragilis ATCC 25285 and B.
thetaiotaomicron ATCC 29741 were used as control
strains.
RT-PCR
The presence of the cfiA gene in Division II B. fragilis
strains was confirmed by RT-PCR, as described by Eitel
et al. [10].
Statistical evaluation
The data were analysed by using Fischer’s exact and
Spearman’s correlation tests in the SigmaPlot 12
program and the significance level was set to 0.05
(i.e. p< .05). The antibiotic resistance data values
were analysed via the chi-square test (v2-test) in
SigmaPlot 12.
Results
Isolates
In our study, 400 clinically relevant Bacteroides strains
were investigated. A sum of 397 samples were taken
after 48 hours of admission to hospital; and three sam-
ples by a General Practitioner (GP). Here, 13% of the iso-
lates were isolated from a pure culture and 87% from a
mixed culture. A total of 43.5% of the patients were
female, 56.5% were male and they had an average age
of 59.3 years (4–101 years). The majority of the isolates
was B. fragilis (58.3%), followed by B. thetaiotaomicron
(19.8%), B. vulgatus (6.5%), B. ovatus (6.0%), P. distasonis
(3.8%), B. uniformis (2.8%); and other B. fragilis group
species (B. caccae, B. nordii, B. salyersiae, B. stercoris, B.
cellulosilyticus, B. intestinalis, P. goldsteinii) were also iden-
tified in low rates (0.3–1%). The most common sample
types were wound (44.8%) and intraabdominal samples
(42.7%); while extraabdominal abscess (3.8%), blood cul-
ture (4.2%) and other types (gynaecological samples,
middle ear, cerebrospinal fluid, pericardial fluid) (4.5%)
were less frequent. Half of the strains were collected in
Surgery, 12.7% in an Intensive Care Unit (ICU), 12.5% in
Internal Medicine, 5.8% in Pediatrics, 5.0% in Obstetrics
and Gynaecology, and the remaining samples were col-
lected in other departments (1.0–4.5%).
Antibiotic susceptibility
The data of antimicrobial susceptibility, the MIC ranges,
the MIC50 and MIC90 values are summarized in Table 1.
A total of 98% of the strains were resistant to ampicillin
and the overall resistance rate to moxifloxacin was
18.5%. A sum of 36.75% of the isolates displayed resist-
ance to clindamycin. CLSI breakpoints indicated a high
resistance of 65.25% to tetracycline. On the other hand,
only 4.5% displayed resistance to amoxicillin/clavulanic
acid. Metronidazole remained very active against
Bacteroides species, with only one strain demonstrating
resistance (0.25%). Most of the isolates (94.75%) were
susceptible to tigecycline, only four strains being resist-
ant to this antibiotic agent. Chloramphenicol also
remained very active against Bacteroides species; with
99.5% of the strains were fully susceptible, and no resist-
ant isolates was found. The rate of cefoxitin resistant
Table 1. Continued
MIC (mg/ml) % of isolates
Antimicrobial agents Range MIC50 MIC90 Susceptible Intermediate Resistant
Metronidazole 0.125–0.5 0.5 1 100.00 0.00 0.00
Moxifloxacin 0.5–32 0.25 1 72.72 9.10 18.18
Tetracycline 0.125–32 8 32 54.55 18.18 27.27
Tigecycline 0.064–2 0.5 2 100.00 0.00 0.00
Chloramphenicol 4–8 8 8 100.00 0.00 0.00
Other Bacteroides speciesa (n¼ 12)
Ampicillin 2 to >256 64 64 0.00 0.00 100.00
Amoxicillin/clavulanic acid 0.125–4 0.5 4 100.00 0.00 0.00
Cefoxitin 1–64 16 32 41.67 41.67 16.67
Meropenem 0.125–2 0.5 1 100.00 0.00 0.00
Clindamycin 0.125 to >256 4 >256 41.67 0.00 58.33
Metronidazole 0.125–2 0.5 1 100.00 0.00 0.00
Moxifloxacin 0.064–64 2 16 66.67 8.33 25.00
Tetracycline 0.25–128 16 128 16.67 8.33 75.00
Tigecycline 0.125–32 0.25 16 75.00 0.00 25.00
Chloramphenicol 0.25–16 4 8 91.67 8.33 0.00
aB. stercoris (1), B. cellulosilyticus (1), B. caccae (4), B. intestinalis (1), B. salyersiae (2), B. nordii (2), P. goldsteinii (1).
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strains was 6.75% and we found the meropenem resist-
ance rate of 7% (Table 1).
Comparing the resistance rates of the different spe-
cies, 91.67–100% of the species were resistant to ampi-
cillin. P. distasonis strains had the highest resistance
rates to amoxicillin/clavulanic acid (26.67%) and cefoxitin
(20%). A total of 16.66% of the B. ovatus strains were
resistant to meropenem; whilst all of the P. distasonis, B.
uniformis and other Bacteroides species were susceptible
to this drug. The resistance rate of 55.7% for clindamycin
was found among B. thetaiotaomicron, whilst 25.75% of
the B. fragilis isolates were resistant to this drug.
Antibiotic susceptibility data values of the centres are
summarized in Table 2. A significant difference among
highly ampicillin resistant (64mg/l) strains was
observed between centre pairs: Centres 1 and 4
(p< .001); Centres 2 and 4 (p< .001); Centres 2 and 4
(p¼ .002). Comparing the cefoxitin resistant rates of the
centres, the difference was significant between Centre 3
(3.00%) and Centre 4 (13.00%) (p< .001). We detected a
relatively high difference in meropenem susceptibility
data. A total of 28 meropenem resistant strains were
found, 25 of them were B. fragilis (89.28%, 25/28).
Interestingly, in Centre 4, we identified 11 B. fragilis
(39.28%, 11/28) and one B. ovatus (3.57%, 1/28) merope-
nem resistant strains. All of these B. fragilis strains were
identified as a member of the Division II by MALDI-TOF
MS and harboured the cfiA gene proved by RT-PCR. In
Table 2. Antibiotic susceptibility of B. fragilis group isolates obtained from the different Hungarian centres.
% of isolates
Antimicrobial agents MIC (mg/l) range Susceptible Intermediate Resistant
Centre 1 (n¼ 100)
Ampicillin 4–512 0.00 5.00 95.00
64mg/l 62.00
Amoxicillin/clavulanic acid 0.064–16 92.00 5.00 3.00
Cefoxitin 1–128 77.00 16.00 7.00
Meropenem 0.125–32 95.00 1.00 4.00
Clindamycin 0.125 to >256 52.00 0.00 48.00
Metronidazole 0.125–4 100.00 0.00 0.00
Moxifloxacin 0.25–32 71.00 7.00 22.00
Tetracycline 0.125–128 31.00 6.00 63.00
Tigecycline 0.125–32 89.00 7.00 4.00
Chloramphenicol 0.25–8 100.00 0.00 0.00
Centre 2 (n¼ 100)
Ampicillin 2–512 1.00 0.00 99.00
64mg/l 57.00
Amoxicillin/clavulanic acid 0.064–32 89.00 9.00 2.00
Cefoxitin 1–128 77.00 19.00 4.00
Meropenem 0.25–32 92.00 3.00 5.00
Clindamycin 0.064 to >256 63.00 0.00 37.00
Metronidazole 0.064–4 100.00 0.00 0.00
Moxifloxacin 0.125–32 72.00 9.00 19.00
Tetracycline 0.125–256 27.00 10.00 63.00
Tigecycline 0.064–16 97.00 1.00 2.00
Chloramphenicol 2–16 98.00 2.00 0.00
Centre 3 (n¼ 100)
Ampicillin 2 to >256 2.00 0.00 98.00
64mg/l 73.00
Amoxicillin/clavulanic acid 0.125–32 89.00 8.00 3.00
Cefoxitin 0.5–128 80.00 17.00 3.00
Meropenem 0.125–32 87.00 6.00 7.00
Clindamycin 0.064 to >256 73.00 0.00 27.00
Metronidazole 0.064–16 99.00 0.00 1.00
Moxifloxacin 0.125–64 78.00 5.00 17.00
Tetracycline 0.25–128 35.00 4.00 61.00
Tigecycline 0.064–8 99.00 1.00 0.00
Chloramphenicol 0.125–8 100.00 0.00 0.00
Centre 4 (n¼ 100)
Ampicillin 16 to >256 0.00 0.00 100.00
64mg/l 91.00
Amoxicillin/clavulanic acid 0.5–16 77.00 14.00 6.00
Cefoxitin 1–256 74.00 13.00 13.00
Meropenem 0.064–32 81.00 7.00 12.00
Clindamycin 0.064 to >256 65.00 0.00 35.00
Metronidazole 0.125–4 100.00 0.00 0.00
Moxifloxacin 0.25–64 79.00 5.00 16.00
Tetracycline 0.125–128 22.00 4.00 74.00
Tigecycline 0.064–8 95.00 5.00 0.00
Chloramphenicol 4–8 100.00 0.00 0.00
Centre 1: Semmelweis University, Budapest; Centre 2: SYNLAB Ltd., Budapest; Centre 3: University of Debrecen; Centre 4:
University of Szeged.
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Centre 4, we found 11 high-level-meropenem-resistant
strains (MIC 16mg/l) and two cfiA-positive strains with
MIC-values of 4mg/l and 8mg/l. In other centres, the
rate of meropenem resistant strains was lower (4.0–7.0%)
(Table 1) and all of them were high-level-meropenem-
resistant (MIC 16mg/l). A significant difference in
meropenem resistance was observed between Centres 1
and 4 (p< .001) (Table 3). Clindamycin resistance dis-
played a relatively strong geographical difference, which
was significant between Centre 1 (48.0%) and Centre 3
(27.00%) (p¼ .003). The highest resistance rate to tetra-
cycline was found among the strains isolated in Centre 1
(63.0%); while in Centre 4 this rate was 74.0%; but the
difference was not significant (p¼ .121) (Table 3). With a
correlation analysis, a strong correlation (p< .05) was
observed with the following antimicrobial drug pairs on
the rate of resistant strains: ampicillin and amoxicillin/
clavulanic acid; cefoxitin and amoxicillin/clavulanic acid;
tetracycline and tigecycline. We analysed the antibiotic
susceptibility data based on the clinical source, but we
did not find any significant correlation (i.e. p< .05).
Discussion
In our study, we found a very high ampicillin resistance
rate (98.0%) due to the widely distributed b-lactamase
producing genes among Bacteroides isolates, which is
concordant with the results published by Nagy et al.
(2008–2009) (97.4%) [3]. Only 4.5% of our isolates were
resistant to amoxicillin/clavulanic acid, while Nagy et al.
(2008–2009) reported a rate of 8.7% [3] and Wybo et al.
(2011–2012) a rate of 14% [11]. Some 6.75% of the
strains exhibit a resistance to cefoxitin, which is much
lower than reported in previous surveys (15.2–17.2%)
[3,6]. The background of decreased amoxicillin/clavulanic
acid and cefoxitin resistance rate may be the different
collection sites, change of the antibiotic usage, the dif-
ferent number of the isolates. The background of the
reduction of cefoxitin resistance rate can be its very low
usage. Interestingly, the consumption of amoxicillin/clav-
ulanic acid is high and this was the first choice in
Bacteroides infections, the resistant rate remained quite
low. However, the comparison of data of present and
previous Hungarian studies is quite difficult because of
the different methods (microbroth dilution [12] vs. agar
dilution [3]), different breakpoints and number of iso-
lates. The rate of cefoxitin resistance depends on the dif-
ferent species: for instance, 3.44% of the B. fragilis and
20% of the P. distasonis strains were resistant. This find-
ing is in agreement with Snydman et al. (2010–2012),
who found that 3.7% of the B. fragilis and 14.7% of the
P. distasonis were resistant to cefoxitin [13]. In general,
carbapenems show high activity against anaerobic bac-
teria, but there is a threat of increasing carbapenem
resistance rate [14,15]. A meropenem resistance rate of
0.5% for the B. fragilis group isolates was reported in an
American study [16], and in Europe it was 1.3% [17];
however, Liu et al. (2000–2007) found a resistance rate
of 12% of B. fragilis strains in Taiwan [15]. In our study,
we found an overall species resistance level of 7% to
meropenem, and 9.87% of B. fragilis strains resistant to
meropenem, which rates were relatively higher in com-
parison to that of reported by American and European
studies [16,17]. Studies have reported a prevalence of
cfiA-positivity of between 2.4 and 5.7% [18–20]; and
8.58% of 233 B. fragilis strains harboured the cfiA gene
(Table 3). The difference of the meropenem resistance
rates among the centres can be the different prevalence
of the cfiA gene and the local antibiotic administration.
According to the literature, the meropenem resistance
mechanism of cfiA-negative B. fragilis strains can be the
alteration of the penicillin binding proteins (PBPs) and/or
decreased permeability [1]. We noticed an elevated over-
all resistance level of 36.75% to clindamycin, which var-
ied among the different species. This rate was lowest
among B. fragilis isolates (25.75%) and highest among B.
thetaiotaomicron (55.7%) strains. Others have reported a
clindamycin resistance rate of between 27% and 37.6%
[3,21,22]. We found that clindamycin resistance displayed
a relatively strong geographical difference, which is con-
cordant with the results published by Nagy et al.: in the
Southern European countries, the mean rate of clinda-
mycin resistant strains was 37.6%; however, in Northern
Europe, it was found to be 81.4% [3]. Despite the
Table 3. Meropenem MIC values of cfiA-positive and -negative B.
fragilis and Bacteroides non-fragilis isolates.
Meropenem MIC (mg/l) Centre 1 Centre 2 Centre 3 Centre 4
cfiA-positive B. fragilis
16 1 2 3 11
8 1
4 1
<4 1
cfiA-negative B. fragilis
16 2 3 2
8
4
<4
Non-fragilis Bacteroides
16 2a 1b
8
4
<4
aB. ovatus, B. thetaiotaomicron.
bB. ovatus.
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frequent usage of metronidazole, this drug still showed
excellent activity against Bacteroides isolates, only one
strain was resistant to metronidazole (0.25%). The overall
resistance rate to metronidazole among Bacteroides iso-
lates remained low (<1%) [3,5,6]. Among the different
Bacteroides species, the moxifloxacin resistance rate
varies considerably; all of the P. distasonis (n¼ 15) iso-
lates were susceptible, but 15.45% of the B. fragilis
(n¼ 233) and 50% of the B. vulgatus (n¼ 26) strains
were resistant to moxifloxacin. Considerable differences
in moxifloxacin susceptibility between species were
observed by Snydman et al. (2010–2012): the resistance
rate varied from 38.9% in P. distasonis to over 70% of B.
ovatus, B. vulgatus and other Bacteroides spp. (B. caccae,
B. eggerthii, etc.) [12]. Nagy et al. reported significant
regional differences of the rates of moxifloxacin resist-
ance strains from Southern (92.45%) and Northern
European (70.1%) countries [3] and we found particular
geographical differences (Centre 3: 3% vs. Centre 4:
13%) in Hungary. We detected an overall resistance rate
to tetracycline of 65.25%, but there was also a great vari-
ation; with 27.27% of the B. uniformis (n¼ 11) isolates,
and 75% of the other Bacteroides isolates (n¼ 12) were
resistant to this drug, and an overall rate of 65.25%.
Tigecycline was very active, only three resistant strains
were isolated (1.5%), which result was consistent with
the results published by Nagy et al. (2008–2009) (1.7%)
[3]. The effectiveness of chloramphenicol remained
excellent, and with the exception of one intermediate
susceptible strain, all were susceptible to chlorampheni-
col. Our result was concordant with other studies: Wybo
et al. reported a susceptibility rate of 99% of 2004 [11],
and Nitzan et al. found that 98.5% (2012) of anaerobic
isolates were susceptible to chloramphenicol [23].
Only a limited comparison could be made among pre-
sent and previous Hungarian Bacteroides spp. resistance
data. However, according to the data reported by Nagy
et al., the level of clindamycin resistance increased from
23% (1992) to 36.75% and moxifloxacin from 13.6%
(2008–2009) to 18.50%, but the level of resistance to
amoxicillin/clavulanic acid decreased from 15%
(2008–2009) to 4.5% and cefoxitin from 24%
(2008–2009) to 6.75% (Table 4) [3,13]. In general, we
observed a strong correlation (p< .05) among the fol-
lowing three pairs: ampicillin and amoxicillin/clavulanic
acid; cefoxitin and amoxicillin/clavulanic acid; and tetra-
cycline and tigecycline. In the background, there could
be common antibiotic resistance mechanisms: the b-lac-
tamase production is the most common resistance
mechanism for b-lactam antibiotics among B. fragilis
isolates; more than 90% of the isolates express at least
one b-lactamase gene [1]. Among the important b-lac-
tam resistance genes, Rogers et al. described the cepA
cephalosporinase gene, the encoded enzyme hydrolyses
penicillins and most of the cephalosporins (except for
cefoxitin) [24]. Another resistance gene, the cfxA is
responsible for the cefoxitin resistance and usually posi-
tioned on mobilizable transposons, e.g. Tn4555 [10]. The
carbapenem resistance is associated with the chromo-
somal cfiA gene, which encodes Zn2þ-dependent met-
allo-b-lactamase. For the expression of cfiA gene, the
presence of an IS element required in the upstream
region (e.g. IS613, IS1169, IS614B, IS4351, IS1186 or
IS1187) [17]. The other resistance mechanisms are
decreased permeability or the alteration of PBPs [1].
Against tetracycline, Bacteroides isolates can express
active efflux, encoded by the tetA, tetB, tetC, tetD, tetE,
etc. genes. Many Bacteroides strains express ribosomal
protection proteins, encoded by tetQ, tet32, tet36, tetM,
tetO, etc. genes. Bartha et al. reported elevated tigecyc-
line MIC-value (8mg/l) in tetQ-harbouring B. fragilis
group isolates. The enzymatic modification is not import-
ant among anaerobic bacteria, because enzymes
encoded by tetX and tetX1 require both oxygen and
NADPH for its activity; however, 75% of the B. fragilis
group isolates with tigecycline MIC =4mg/l harboured
tetX1 gene [25].
Conclusions
Currently, no valid, exact data about antibiotic prescrib-
ing practices are available in Hungary. The rational
restriction of antibiotics can help the control of other
diseases, e.g. C. difficile infection. In the past decade, the
number of reports of b-lactam/b-lactamase inhibitor
combinations, cefoxitin, moxifloxacin, tetracycline and
Table 4. Comparison of previous Hungarian resistance data and
data taken from the present study of B. fragilis group isolates.
Percentage (%) of resistance strains at different timepoints
Antimicrobial agents
1992
(n¼ 200)
[25]
2010
(n¼ 100)
[4]
Present
study
(n¼ 400)
Ampicillin 97 100 98.00
Amoxicillin/clavulanic acid ND 15 4.50
Cefoxitin 11 24 6.75
Meropenem ND ND 7.00
Clindamycin 23 27 36.75
Metronidazole 0 1 0.25
Moxifloxacin ND 13.6 18.50
Tetracycline 65 ND 65.25
Tigecycline ND 1.7 1.50
Chloramphenicol 0 ND 0
ND: no data.
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clindamycin resistant B. fragilis group isolates has
increased worldwide [25,26]. The reasons for different
resistance patterns maybe due to local antimicrobial
chemotherapy administration, the distribution of anti-
biotic resistance genes, the variation between suscepti-
bility testing methods, the differences in the
interpretative breakpoints or the complete lack of them.
The main conclusion of our survey and our results
proved that the periodic monitoring of the antimicrobial
susceptibility of Bacteroides species is essential to obtain
accurate information on local and national rates of anti-
microbial resistance, and that this is critical to guide
appropriate therapy for patients.
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